Related Experiment Video
Updated: Mar 10, 2026
08:04
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
12.8K
Successful Immune Checkpoint Inhibitor Rechallenge After Sintilimab-Induced Pancreatitis: A Case Report
Hao Shi1, Lin Ye1, Qinrong Mo1
1Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, People's Republic of China.
International Medical Case Reports Journal
|March 9, 2026
Summary
Immune checkpoint inhibitors (ICIs) can cause pancreatitis in advanced hepatocellular carcinoma (HCC) patients. Resuming ICI therapy after pancreatitis resolution can safely control the cancer and prevent recurrence.
Area of Science:
- Oncology
- Immunology
- Gastroenterology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer death in China.
- Immune checkpoint inhibitors (ICIs) have improved advanced HCC treatment but can cause immune-related adverse events (irAEs).
- Immune checkpoint inhibitor-related pancreatitis (ICIPI) is a rare but serious irAE.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
450
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
450
01:30Acute Pancreatitis II: Clinical Manifestations and Management
994
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
994